02/19/2026
Big news! ChartCheck Adaptive is now USFDA 510(k) cleared and already making an impact globally. We’re proud to announce the initial deployment of ChartCheck Adaptive across 15 Icon Group cancer centres in Australia.
“Having automated, quantitative insight into daily treatment progression supports confidence in clinical decision making without adding burden to our teams and, most importantly, delivering quality patient care,” shares Trent Aland, Executive Manager, Clinical Care at Icon Group.
With positive early results already seen, this rollout reflects the growing clinical value of offline adaptive assessment at scale. Read the press release: https://bit.ly/4qLQaRJ